AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33242991 — intervention group
Group type: COMPARATOR
Intervention: Non-concussive headaches
Number of subjects: 1094
Study 33243016 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Education and Physical Activity (TEPA)
Number of subjects: 40
Study 33243016 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic Education
Number of subjects: 40
Study 33243049 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus obinutuzumab (BG)
Number of subjects: 0
Study 33243149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric prilocaine (35 to 50 mg) co-administered with 2.5 mcg of sufentanil and 100 mcg of morphine
Number of subjects: 0
Study 33243149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric prilocaine with sufentanil and morphine
Number of subjects: 0
Study 33243204 — intervention group
Group type: EXPERIMENTAL
Intervention: Community gardening participation
Number of subjects: 66
Study 33243204 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-gardeners)
Number of subjects: 66
Study 33243251 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0
Study 33243251 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 33243251 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 33243251 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombospondin 1 (TSP1) treatment
Number of subjects: 0
Study 33243251 — intervention group
Group type: COMPARATOR
Intervention: Control (macular hole patients)
Number of subjects: 0
Study 33243252 — intervention group
Group type: COMPARATOR
Intervention: Traditional school children during summer vacation (Condition 1 to 2)
Number of subjects: 285
Study 33243252 — intervention group
Group type: COMPARATOR
Intervention: Year-round school children during summer vacation (Condition 2 to 3)
Number of subjects: 285
Study 33243252 — intervention group
Group type: COMPARATOR
Intervention: Traditional school children (Condition 2)
Number of subjects: 285
Study 33243252 — intervention group
Group type: COMPARATOR
Intervention: Year-round school children (Condition 3)
Number of subjects: 285
Study 33243378 — intervention group
Group type: EXPERIMENTAL
Intervention: BAV patients after TAVR
Number of subjects: 204
Study 33243378 — intervention group
Group type: COMPARATOR
Intervention: TAV patients after TAVR
Number of subjects: 204
Study 33243789 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-bout sedentary behaviour (≥90 min) in patients with diabetes mellitus (DM)
Number of subjects: 379
Study 33243789 — intervention group
Group type: COMPARATOR
Intervention: Sedentary behaviour (general)
Number of subjects: 379
Study 33243800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) combined with Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU)
Number of subjects: 12
Study 33243816 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised nurse-led education sessions
Number of subjects: 30
Study 33244300 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejuveinix
Number of subjects: 0
Study 33244300 — intervention group
Group type: COMPARATOR
Intervention: Lipopolysaccharide-Galactosamine Mouse Model
Number of subjects: 0
Study 33244458 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg/d
Number of subjects: 0
Study 33244458 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg/d
Number of subjects: 0
Study 33244711 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil ophthalmic solution 0.02% (n=8)
Number of subjects: 12
Study 33244711 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (n=4)
Number of subjects: 12
Study 33244719 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery for rectal cancer
Number of subjects: 323
Study 33245115 — intervention group
Group type: EXPERIMENTAL
Intervention: GBM stem-like cells (GSLCs) grown in classical 2D culture and in 3D-tumor organoids
Number of subjects: 2
Study 33245115 — intervention group
Group type: EXPERIMENTAL
Intervention: GBM stem-like cells (GSLCs)
Number of subjects: 2
Study 33245172 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB01A, a microtubule inhibitor, administered intravenously for 3 hours once every 21 days, starting dose 2 mg/m², escalated to a maximum tolerated dose (MTD) of 24 mg/m².
Number of subjects: 0
Study 33245179 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 0
Study 33246099 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized 6-min walk test (6MWT)
Number of subjects: 0
Study 33246186 — intervention group
Group type: EXPERIMENTAL
Intervention: Common care pathways (5 identified pathways)
Number of subjects: 3133
Study 33246186 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of transitions (median 3, interquartile range 2-3)
Number of subjects: 3133
Study 33246186 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and injury-related factors (increased age, violence as cause of injury, pre-injury systemic disease, intracranial and overall injury severity, regions of Southern/Eastern Europe)
Number of subjects: 3133
Study 33246388 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban Zen Integrative Therapy (UZIT)
Number of subjects: 13
Study 33246407 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health care (HHC)
Number of subjects: 600
Study 33246438 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of coherence (SOC)
Number of subjects: 4918
Study 33246438 — intervention group
Group type: COMPARATOR
Intervention: Patients without neoplasms
Number of subjects: 4918
Study 33246478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound shear wave elastography (SWE) for assessing diaphragm function
Number of subjects: 30
Study 33246478 — intervention group
Group type: EXPERIMENTAL
Intervention: Various pressure support settings and spontaneous breathing trial (SBT)
Number of subjects: 30
Study 33246478 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rate comparison
Number of subjects: 30
Study 33246496 — intervention group
Group type: EXPERIMENTAL
Intervention: Case study design methodology for process evaluation
Number of subjects: 0
Study 33246496 — intervention group
Group type: EXPERIMENTAL
Intervention: Case study design
Number of subjects: 0
Study 33246496 — intervention group
Group type: EXPERIMENTAL
Intervention: Core components of process evaluation
Number of subjects: 0
Study 33246589 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia (SP) group
Number of subjects: 126
Study 33246589 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (HC) group
Number of subjects: 126
Study 33246973 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxycytidine and deoxythymidine therapy
Number of subjects: 6
Study 33247014 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical or systemic treatments for atopic dermatitis (AD)
Number of subjects: 0
Study 33247014 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33247029 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban areas
Number of subjects: 211
Study 33247178 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT3 and TP53 mutations
Number of subjects: 0
Study 33247327 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33247912 — intervention group
Group type: EXPERIMENTAL
Intervention: Live donor uterus transplantation
Number of subjects: 9
Study 33247912 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient costs
Number of subjects: 9
Study 33247912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost components
Number of subjects: 9
Study 33247912 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care perspective
Number of subjects: 9
Study 33248099 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33248295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic prophylaxis
Number of subjects: 3296
Study 33248295 — intervention group
Group type: COMPARATOR
Intervention: No pharmacologic prophylaxis
Number of subjects: 3296
Study 33248442 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 1055
Study 33248442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomy/Ishtmusectomy (L/I)
Number of subjects: 1055
Study 33248442 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Thyroidectomy (TT)
Number of subjects: 1055
Study 33248442 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from AS to surgery due to disease progression
Number of subjects: 1055
Study 33248473 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 0
Study 33248473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33248962 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR (Cardiovascular Magnetic Resonance)
Number of subjects: 125
Study 33248962 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DE (2-dimensional echocardiography)
Number of subjects: 125
Study 33248962 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DE-GLS (2-dimensional echocardiography Global Longitudinal Strain)
Number of subjects: 125
Study 33248962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagged-CMR GLS (Cardiovascular Magnetic Resonance Global Longitudinal Strain)
Number of subjects: 125
Study 33248962 — intervention group
Group type: EXPERIMENTAL
Intervention: FT-GCS (Feature-Tracking Global Circumferential Strain)
Number of subjects: 125
Study 33248962 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR and 2DE-LVEF (Left Ventricular Ejection Fraction)
Number of subjects: 125
Study 33248962 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DE-GLS
Number of subjects: 125
Study 33248962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2DE-LVEF or LVESVi and strain
Number of subjects: 125
Study 33248962 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR left ventricular ejection fraction and FT strain
Number of subjects: 125
Study 33248962 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DE GLS
Number of subjects: 125
Study 33248965 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning identified 6 clusters for low FFR, relevant features include minimum lumen area, percent atheroma volume, fibrofatty and necrotic core volume, plaque volume, proximal left anterior descending coronary artery lesion, and remodeling index.
Number of subjects: 1013
Study 33248965 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental prognostic value of 6 relevant features over percent diameter stenosis and FFR.
Number of subjects: 1013
Study 33248965 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year vessel-oriented composite outcome risk increased with every increment of the number of 6 relevant features.
Number of subjects: 1013
Study 33249200 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD/cardiac resynchronization therapy - defibrillator replacement
Number of subjects: 983
Study 33249510 — intervention group
Group type: EXPERIMENTAL
Intervention: Less robust 24-h rest-activity rhythms (lower relative amplitude)
Number of subjects: 411
Study 33249510 — intervention group
Group type: EXPERIMENTAL
Intervention: Less robust rest-activity rhythms
Number of subjects: 411
Study 33249569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients (SS)
Number of subjects: 232
Study 33249569 — intervention group
Group type: COMPARATOR
Intervention: Healthy adult controls (AA)
Number of subjects: 232
Study 33249569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients (SS) with retinopathy
Number of subjects: 232
Study 33249569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients (SS) with a history of priapism
Number of subjects: 232
Study 33249569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients (SS) with leg ulcers
Number of subjects: 232
Study 33249636 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment for 16 weeks
Number of subjects: 40
Study 33249636 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 40
Study 33249802 — intervention group
Group type: EXPERIMENTAL
Intervention: UST 130 mg
Number of subjects: 133
Study 33249802 — intervention group
Group type: EXPERIMENTAL
Intervention: UST 6 mg/kg
Number of subjects: 133
Study 33249802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 33249802 — intervention group
Group type: EXPERIMENTAL
Intervention: UST 90 mg q12w
Number of subjects: 133
Study 33249802 — intervention group
Group type: EXPERIMENTAL
Intervention: UST 90 mg q8w
Number of subjects: 133
Study 33249870 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurovascular contact with morphological changes on the symptomatic side
Number of subjects: 63
Study 33249870 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurovascular contact with morphological changes on the asymptomatic side
Number of subjects: 63
Study 33249870 — intervention group
Group type: EXPERIMENTAL
Intervention: Demyelination along the intrapontine trigeminal afferents
Number of subjects: 63
Study 33249870 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular decompression
Number of subjects: 63
Study 33249901 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 189
Study 33249933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative pain management techniques
Number of subjects: 0
Study 33249933 — intervention group
Group type: COMPARATOR
Intervention: Standard pain management
Number of subjects: 0
Study 33250039 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) with cutoff <26
Number of subjects: 521
Study 33250039 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) with cutoff <27
Number of subjects: 521
Study 33250131 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L-PEG
Number of subjects: 1004
Study 33250131 — intervention group
Group type: COMPARATOR
Intervention: 4L-PEG
Number of subjects: 1004
Study 33250788 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral paradigms to facilitate treatment development
Number of subjects: 0
Study 33250848 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33251157 — intervention group
Group type: EXPERIMENTAL
Intervention: Griffithsin (GRFT)
Number of subjects: 0
Study 33251516 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral ascorbic acid (1,500 mg), hydrocortisone (50 mg), and thiamine (100 mg) every 6 hours for 4 days
Number of subjects: 117
Study 33251516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 33251691 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (nine infusions during the first 2 months posttransplant)
Number of subjects: 20
Study 33251691 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 20
Study 33251753 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioural therapy (Tele-CBT)
Number of subjects: 10
Study 33251774 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment with non-flow limiting dissection
Number of subjects: 227
Study 33251774 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment with flow limiting dissection
Number of subjects: 227
Study 33251774 — intervention group
Group type: COMPARATOR
Intervention: Drug-coated balloon (DCB) treatment
Number of subjects: 227
Study 33251855 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic events
Number of subjects: 347
Study 33251855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontraumatic events
Number of subjects: 347
Study 33251855 — intervention group
Group type: EXPERIMENTAL
Intervention: No events
Number of subjects: 347
Study 33252266 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 0
Study 33252283 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted retrieval using a laser sheath powered by 308-nm XeCl excimer laser system (CVX-300; Spectranetics) after failed standard retrieval methods.
Number of subjects: 500
Study 33252283 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted retrieval
Number of subjects: 500
Study 33252292 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF treatment interrupted or postponed due to COVID-19
Number of subjects: 524
Study 33252292 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent on COVID-19 related news per day
Number of subjects: 524
Study 33252292 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner with evidence of psychological disorder
Number of subjects: 524
Study 33252292 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of poor ovarian reserve, endometriosis, or uterine fibroids (in females)
Number of subjects: 524
Study 33252313 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum plasma B vitamin and homocysteine profiles
Number of subjects: 0
Study 33252344 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief sleep intervention in infancy
Number of subjects: 734
Study 33252344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sleep intervention)
Number of subjects: 734
Study 33252344 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at age 11 years
Number of subjects: 734
Study 33252344 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 734
Study 33252347 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth interventions integrating PSD principles and BCTs
Number of subjects: 23
Study 33252347 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCTs)
Number of subjects: 23
Study 33252347 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive System Design (PSD) principles
Number of subjects: 23
Study 33252347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BCTs and PSD principles
Number of subjects: 23
Study 33252547 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-C (T and TT variants - rs10484554)
Number of subjects: 333
Study 33252547 — intervention group
Group type: COMPARATOR
Intervention: ZNRD1 (T allele - rs3869068)
Number of subjects: 333
Study 33252547 — intervention group
Group type: EXPERIMENTAL
Intervention: ZNRD1 (CT and TT genotypes - rs3869068)
Number of subjects: 333
Study 33252834 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 739
Study 33252834 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 E6 oncoprotein (E6)
Number of subjects: 739
Study 33252834 — intervention group
Group type: EXPERIMENTAL
Intervention: p16/Ki-67 dual-stained cytology (DS)
Number of subjects: 739
Study 33252834 — intervention group
Group type: COMPARATOR
Intervention: Direct referral of all HPV16/18-positive women
Number of subjects: 739
Study 33252930 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomated tracking of fluid consumption
Number of subjects: 31
Study 33253089 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg subcutaneous (s.c.)
Number of subjects: 1602
Study 33253089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1602
Study 33253089 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg s.c. in fast progressors
Number of subjects: 1602
Study 33253089 — intervention group
Group type: COMPARATOR
Intervention: Placebo in fast progressors
Number of subjects: 1602
Study 33253198 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic malaria
Number of subjects: 1118
Study 33253198 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical malaria
Number of subjects: 1118
Study 33253641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical nadofaragene firadenovec (75 mL dose, 3×10^11 viral particles)
Number of subjects: 157
Study 33253641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical nadofaragene firadenovec
Number of subjects: 157
Study 33253692 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) based on surface multifield technology applied to the contralesional wrist and finger extensors during the turn on the light task (TOTL).
Number of subjects: 11
Study 33253997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib, median average daily dose 40.0 mg, treatment duration median 7.6 months
Number of subjects: 410
Study 33253997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib initiation at 60 mg/day
Number of subjects: 410
Study 33254134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ventralis oralis posterior/ventralis intermedius (Vop/Vim) deep brain stimulation (DBS)
Number of subjects: 4
Study 33255613 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wavelength narrow-bandwidth light
Number of subjects: 0
Study 33255613 — intervention group
Group type: COMPARATOR
Intervention: Long-wavelength narrow-bandwidth light
Number of subjects: 0
Study 33255658 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) combined with non-pegylated liposomal doxorubicin (NPLD)
Number of subjects: 0
Study 33256053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive conflicts in BPD patients
Number of subjects: 0
Study 33256377 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) 50 mg/day to a maximum of 150 mg/day for 16 weeks
Number of subjects: 25
Study 33256377 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG)
Number of subjects: 25
Study 33256590 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-procedural management of edoxaban
Number of subjects: 1442
Study 33256726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors
Number of subjects: 267153
Study 33256726 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple myeloma
Number of subjects: 267153
Study 33256769 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Newborn Health Registry (MNHR) intervention
Number of subjects: 579140
Study 33256772 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital anomalies (nervous system, musculoskeletal system, cleft lip and palate)
Number of subjects: 384
Study 33256777 — intervention group
Group type: EXPERIMENTAL
Intervention: Four or more antenatal care (ANC) visits
Number of subjects: 0
Study 33256777 — intervention group
Group type: COMPARATOR
Intervention: Infants born weighing < 1000 g
Number of subjects: 0
Study 33256777 — intervention group
Group type: COMPARATOR
Intervention: Infants born weighing 1000-1499 g
Number of subjects: 0